What is NAMS's current stock price?

NAMS (NewAmsterdam Pharma Company N.V.) is currently trading at $35.44 with a market cap of $4.14B.

What sector is NewAmsterdam Pharma Company N.V. in?

NewAmsterdam Pharma Company N.V. (NAMS) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is NAMS a good stock to buy?

Analysts have a Buy consensus on NAMS with a price target of $46.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

NAMS NewAmsterdam Pharma Company N.V.

Healthcare

$35.44-0.84%ClosedMarket Cap: $4.14B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

6.45

P/S

183.61

EV/EBITDA

-15.90

DCF Value

$3.54

FCF Yield

-3.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

97.5%

Operating Margin

-953.6%

Net Margin

-942.8%

ROE

-29.8%

ROA

-29.0%

ROIC

-32.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$3.0M	$-48.4M	$—
Q4 null	$32.0K	$-74.9M	$—
FY null	$22.5M	$-203.8M	$—
Q3 null	$348.0K	$-72.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$46.00

Target (Median)

$46.00

Target Range

$37.00 - $55.00

3 Strong Buy11 Buy1 Hold0 Sell0 Strong Sell

GuggenheimBuy

2026-02-19

NeedhamBuy

2026-02-18

RBC CapitalOutperform

2026-01-21

StifelBuy

2025-12-16

Goldman SachsNeutral

2025-12-02

Trading Activity

Insider Trades

View All

LANGE LOUIS Gdirector

SellThu Mar 12

LANGE LOUIS Gdirector

SellThu Mar 12

LANGE LOUIS Gdirector

SellTue Mar 10

LANGE LOUIS Gdirector

SellTue Mar 10

Kastelein Johannes Jacob Pieterdirector, officer: Chief Scientific Officer

SellMon Mar 09

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.03

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Peers